Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

S2190000

Sulpiride

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(±)-Sulpiride, (±)-5-(Aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide, (±)-N-1-(Ethylpyrrolidin-2-ylmethyl)-2-methoxy-5-sulfamoylbenzamide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C15H23N3O4S
CAS Number:
15676-16-1
Molecular Weight:
341.43
MDL number:
MFCD00055061
UNSPSC Code:
41116107
PubChem Substance ID:
329824513
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

sulpiride

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CCN1CCCC1CNC(=O)c2cc(ccc2OC)S(N)(=O)=O

InChI

1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)

InChI key

BGRJTUBHPOOWDU-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Sulpiride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H361

Precautionary Statements

P280

Hazard Classifications

Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 2

1 of 2

SR-95531 ≥98% (HPLC), powder

Sigma-Aldrich

S106

SR-95531

(−)-Quinpirole hydrochloride ≥98% (HPLC), solid

Sigma-Aldrich

Q102

(−)-Quinpirole hydrochloride

P Jenner et al.
Advances in biochemical psychopharmacology, 32, 85-103 (1982-01-01)
It can be said that sulpiride exerts a disinhibitory effect in both depression and schizophrenia but this is not associated with mechanisms through which typical antidepressant or anxiolytic agents act. Sulpiride acts selectively as a dopamine receptor antagonist in the
G Serra et al.
Clinical neuropharmacology, 13 Suppl 1, S76-S83 (1990-01-01)
L-Sulpiride is a dopamine (DA)-receptor blocker that acts as an antidepressant at low doses. We have reviewed evidence suggesting that the antidepressant effect of L-sulpiride may depend on the activation of DA transmission secondary to the blockade of DA autoreceptors.
J H Stubbs et al.
Acta psychiatrica Scandinavica, 102(5), 390-393 (2000-12-01)
Schizophrenic patients who are only partially responsive to clozapine pose a therapeutic challenge. In these circumstances some clinicians would consider adding in a second antipsychotic. We present a case report and review evidence for the efficacy of such augmentation strategies.
Sulpiride augmentation for schizophrenia.
Jijun Wang et al.
Schizophrenia bulletin, 36(2), 229-230 (2010-01-12)
Jijun Wang et al.
The Cochrane database of systematic reviews, (1)(1), CD008125-CD008125 (2010-01-22)
Sulpiride may be used in combination with other antipsychotic drugs in the hope of augmenting effectiveness - especially for those whose schizophrenia has proved resistant to treatment. To evaluate the effects of sulpiride augmentation versus monotherapy for people with schizophrenia.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service